New Delhi — The Ministry of External Affairs announced on 20 March 2026 that India will host a two‑day, high‑level BRICS (Brazil, Russia, India, China, South Africa) meeting on drug control from 22‑23 March 2026 at the International Convention Centre. The summit will centre on synthetic narcotics such as fentanyl and its analogues, and on mechanisms for intelligence sharing, precursor‑chemical monitoring and joint law‑enforcement operations among the five member states.
What happened
The Indian government issued a statement outlining the agenda, which includes mapping trans‑regional trafficking routes, creating a shared database of drug‑related crimes, and coordinating interdiction efforts before shipments reach domestic markets. Delegations from Brazil, Russia, China and South Africa are expected to attend, alongside senior officials from India’s Narcotics Control Bureau (NCB), Central Bureau of Investigation (CBI) and Ministry of Home Affairs. The NCB will present seizure data – 1,200 kg of fentanyl‑based substances in the past year, a 15 % rise over the previous period – and highlight recent CBI operations against trans‑national syndicates.
The meeting follows a series of bilateral agreements signed earlier in 2025‑26. In November 2025 India’s Ministry of Home Affairs signed a memorandum of understanding (MoU) with Russia’s Roskomnadzor to exchange data on precursor chemicals. In January 2026 a similar MoU was concluded with China’s State Administration for Market Regulation, focusing on regulation of synthetic‑drug precursors. These accords are intended to lay the groundwork for the joint intelligence‑gathering mechanisms the summit will formalise.
Why it matters
Synthetic opioids, especially fentanyl, have become the fastest‑growing segment of the global illicit drug market. United Nations Office on Drugs and Crime (UNODC) estimates that fentanyl‑related substances accounted for roughly 45 % of overdose deaths in the United States in 2025, and similar trends are emerging in Europe and Asia. By convening the BRICS bloc – which together represents over a third of global GDP and a significant share of international trade routes – the summit offers a platform for coordinated disruption of supply chains that exploit the geographic span of the five economies.
For India, the event serves a dual diplomatic purpose. First, it showcases domestic enforcement successes, reinforcing the country’s credibility in multilateral drug‑control fora. Second, it positions India as a bridge between the traditionally Western‑led United Nations drug‑control architecture and the emerging BRICS consensus, potentially shaping future UNODC reforms.
Background and context
India has seen a steady rise in synthetic‑drug seizures over the past three years. Official NCB figures show a 12 % year‑on‑year increase in fentanyl‑related confiscations between 2023 and 2024, and a further 15 % jump in 2025, as reported in the ministry’s statement. The growth reflects both heightened trafficking activity and expanded detection capabilities, including the deployment of portable mass‑spectrometry units at major ports and border checkpoints.
Internationally, the BRICS nations have been deepening cooperation on security issues since the 2022 BRICS summit in Beijing, which produced a joint declaration on “enhanced collaboration against trans‑national organised crime.” Subsequent joint exercises – notably the 2024 “Operation Silk Route” naval drill involving India, Russia and China – included a focus on interdiction of illicit cargo. The anti‑drugs summit builds on this trajectory, moving from tactical drills to strategic policy coordination.
Competing claims and uncertainty
While Indian officials portray the summit as a decisive step toward curbing synthetic‑drug flows, some analysts caution that divergent legal frameworks and enforcement capacities could limit its impact. Brazil’s drug‑policy approach, for example, emphasizes de‑criminalisation of certain substances, whereas Russia maintains a zero‑tolerance stance. These policy differences may complicate the creation of a unified “shared database” or joint operational protocols.
Moreover, the effectiveness of intelligence sharing hinges on the willingness of member states to disclose sensitive data. Past attempts at multilateral data exchange within BRICS have encountered bureaucratic delays, as noted in a 2025 report by the Center for Strategic and International Studies (CSIS) on BRICS security cooperation. No public details have been released about the specific technical architecture the summit will adopt for data sharing, leaving uncertainty about cybersecurity safeguards and data‑privacy standards.
Finally, the focus on synthetic opioids may overlook other emerging drug threats, such as new psychoactive substances (NPS) that are not covered by existing precursor‑chemical agreements. Critics argue that a narrow emphasis on fentanyl could divert resources from broader drug‑policy reforms, including demand‑reduction and treatment programmes.
What to watch next
– Agenda finalisation – The Ministry of External Affairs is expected to release a detailed agenda by early April 2026. The inclusion of a public‑health session, as requested by Indian officials, will indicate the extent to which the summit will address demand‑side interventions.
– Joint statements – A communique issued at the close of the summit will reveal the concrete commitments made, such as timelines for database deployment or the establishment of a BRICS‑wide precursor‑chemical monitoring centre.
– Follow‑up mechanisms – Observers will look for the creation of a standing working group or secretariat to oversee implementation, and for any scheduled future meetings, including possible rotation of the host country.
– Reactions from civil society – NGOs in India and partner countries have called for transparency on how intelligence will be used and for safeguards against the misuse of data. Their responses to the summit’s outcomes will shape public‑policy debate.
– UNODC engagement – Any alignment of the BRICS anti‑drugs agenda with UNODC’s 2026‑2030 strategic plan could signal a shift in global drug‑control governance away from Western‑centric models.
Conclusion
The two‑day BRICS anti‑drugs summit in New Delhi marks a high‑profile effort by emerging economies to coordinate a response to the synthetic‑opioid crisis that is reshaping global drug markets. India’s role as host allows it to highlight recent enforcement gains while seeking to institutionalise intelligence‑sharing mechanisms that could disrupt trans‑regional trafficking routes. Yet the summit’s success will depend on reconciling divergent legal approaches, securing reliable data exchange, and expanding the focus beyond fentanyl to encompass the broader spectrum of illicit substances. The statements and operational frameworks that emerge in the coming weeks will be the first concrete test of whether BRICS cooperation can translate diplomatic intent into measurable reductions in synthetic‑drug supply and harm.
Sources
– “India to host two‑day BRICS anti‑drugs meet.” The Hindu, 20 March 2026. https://www.thehindu.com/news/national/india-to-host-two-day-brics-anti-drugs-meet/article71186105.ece
Story synopsis gathered from: The Hindu – National — source
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
